15 completed, 7 unknown, 3 not yet recruiting, 2 terminated. 29 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 29 | Completed 15, Unknown 7, Not yet recruiting 3, Terminated 2, Recruiting 1, Withdrawn 1 |
Follow Weight Gain: new trials by email Literature Review of Weight Gain trials Research Report on Weight Gain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery Semaglutide weekly injection, Placebo - Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 100 | 2026-10-01 | 2026-10-05 |
| Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain Semaglutide weekly injection, Placebo - Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 100 | 2026-10-01 | 2026-10-05 |
| Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE) Semaglutide weekly injection, Placabo - Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 104 | 2026-10-01 | 2026-10-05 |
| Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females Adjunctive Aripiprazole for improving Weight and Metabolic Outcomes in Females - Psychosis, Metabolic Syndrome | Phase 4 | Unknown | Universiti Putra Malaysia | 600 | 2024-09-15 | 2024-09-19 |
| Semaglutide 2.4mg for Low Responders After Bariatric Surgery Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY] - Obesity, Obesity, Morbid | Phase 4 | Unknown | Zuyderland Medisch Centrum | 152 | 2024-05-01 | 2024-03-01 |
| The Effect Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) on Small Intestine Gut Wall gastroscopy - HIV Infections, Weight Gain | Phase 4 | Unknown | Jussi Sutinen | 24 | 2023-01-19 | 2023-03-27 |
| Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole Comparison of Risperidone and Aripiprazole - Weight Gain, Autism Spectrum Disorder | Phase 4 | Completed | Vanderbilt University Medical Center | 30 | 2022-02-01 | 2026-10-05 |
| Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF? DOR/3TC/TDF - Hiv, Weight Gain | Phase 4 | Terminated | University Health Network, Toronto | 4 | 2021-04-26 | 2025-07-16 |
| Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] - Hiv, HIV Infections | Phase 4 | Unknown | Thomas Benfield | 126 | 2021-02-02 | 2021-05-27 |
| Progesterone and Resting Energy Expenditure Utrogestan - Menopause, Progesterone | Phase 4 | Terminated | Insel Gruppe AG, University Hospital Bern | 2 | 2019-11-01 | 2022-03-31 |
| Bioenergetic Effects of Aging and Menopause (BEAM) GnRH antagonist, Estrogen Product, Placebo estradiol - Menopause, Obesity, Abdominal | Phase 4 | Recruiting | University of Colorado, Denver | 57 | 2019-09-24 | 2023-12-18 |
| Menopausal Sleep Fragmentation and Body Fat Gain Estradiol withdrawal, Fragmented sleep - Menopause | Phase 4 | Completed | Brigham and Women's Hospital | 41 | 2017-07-15 | 2024-10-08 |
| Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study lorcaserin, Intensive dietary counseling - Weight Gain | Phase 4 | Unknown | Southern California Institute for Research and Education | 15 | 2014-01-01 | 2014-01-30 |
| Lifestyle Intervention to Limit Excessive Weight Gain During Pregnancy in Minority Women Lifestyle Intervention group, Standard of Care - Pregnancy, Weight Gain | Phase 4 | Completed | Guillermo Umpierrez | 57 | 2010-04-01 | 2013-11-21 |
| Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine - Psychotic Disorders | Phase 4 | Completed | Johns Hopkins University | 127 | 2009-01-01 | 2017-04-25 |
| Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults Exenatide, Placebo - Weight Gain | Phase 4 | Completed | University of Cincinnati | 54 | 2008-12-01 | 2018-04-20 |
| Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders aripiprazole - Bipolar Disorders, Metabolic Complication | Phase 4 | Completed | Seoul National University Hospital | 28 | 2008-12-01 | 2013-12-05 |
| Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention, and Weight in Type 2 Diabetic Patients Insulin Detemir; Insulin Insulatard, Insulin Detemir, Insulin Insulatard - Diabetes Type 2, Weight Gain | Phase 4 | Completed | Copenhagen University Hospital, Rigshospitalet | 24 | 2008-06-01 | 2010-01-20 |
| Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia Pramlintide, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 4 | Completed | University of Texas Southwestern Medical Center | 33 | 2007-11-01 | 2018-11-16 |
| Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Abilify (aripiprazole) - Hyperprolactinemia, Weight Gain | Phase 4 | Unknown | Genovate Biotechnology Co., Ltd., | 2007-10-01 | 2007-10-10 |
Showing 20 of 29. Sign in to see all of them.
Obesity (6) · Schizophrenia (6) · Bipolar Disorder (4) · Obesity, Morbid (4) · Psychotic Disorders (4) · Diabetes Mellitus (3) · Metabolic Syndrome (3) · Acquired Immunodeficiency Syndrome (2) · Autism Spectrum Disorder (2) · HIV Infections (2) · Depression (1) · Diabetes Mellitus, Type 1 (1) · Diabetes Mellitus, Type 2 (1) · Drug-Related Side Effects and Adverse Reactions (1)
Body Weight (29) · Body Weight Changes (29) · Pathological Conditions, Signs and Symptoms (29) · Signs and Symptoms (29) · Nutritional and Metabolic Diseases (17) · Mental Disorders (12) · Nutrition Disorders (10) · Overnutrition (10) · Overweight (10) · Metabolic Diseases (9) · Schizophrenia Spectrum and Other Psychotic Disorders (8) · Glucose Metabolism Disorders (7) · Endocrine System Diseases (6) · Bipolar and Related Disorders (4) · Immune System Diseases (4)
Metformin (5) · Aripiprazole (4) · Olanzapine (4) · pramlintide (2) · ziprasidone (2) · Exenatide (1) · Fluoxetine (1) · Gastroscopy (1) · Insulin Aspart (1) · Insulin Detemir (1) · Insulin Glargine (1) · Insulin Lispro (1) · Islet Amyloid Polypeptide (1) · LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- (1) · Lamivudine (1)
General Committee of Teaching Hospitals and Institutes, Egypt (3) · University of Cincinnati (2) · University of Texas Southwestern Medical Center (2) · Brigham and Women's Hospital (1) · Cambridge Health Alliance (1) · Central South University (1) · Charite University, Berlin, Germany (1) · Copenhagen University Hospital, Rigshospitalet (1) · Eli Lilly and Company (1) · Genovate Biotechnology Co., Ltd., (1) · Guillermo Umpierrez (1) · Hamilton Health Sciences Corporation (1) · Insel Gruppe AG, University Hospital Bern (1) · Johns Hopkins University (1) · Jussi Sutinen (1)
United States (12) · Canada (3) · Egypt (3) · Denmark (2) · China (1) · Finland (1) · Germany (1) · Italy (1) · South Korea (1) · Switzerland (1)
Angela Maxwell-Horn, M.D. (1) · Carol A Tamminga, MD (1) · Chen Chih-Ken, PhD (1) · Christoph Correll, MD (1) · Emmanuel Stip, MD, M.Sc. (1) · Gloria Reeves, MD (1) · Guillermo Umpierrez, MD (1) · Hadine Joffe, MD MSc (1) · Jan Willem Greve, prof (1) · Jean A Frazier, MD (1) · Jeffrey T Rado, M.D. (1) · Jingping Zhao, MD (1) · Jussi Sutinen (1) · Kyooseob Ha, MD, PhD (1)
PMID 17539698, PMID 18182600, PMID 20732372, PMID 22002075, PMID 22398127, PMID 22714121, PMID 25886678, PMID 27091719, PMID 27147592, PMID 30542300, PMID 33800403, PMID 37130314, PMID 39039812, PMID 40203970
2018 (1), R01AG053838 (1), R01MH080270 (1), U54AG062319 (1)